Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis

Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis

Tofacitinib is approved for several immune-mediated inflammatory diseases, but safety concerns have recently been raised. We searched PubMed (accessed on 27 February 2023) for original articles regarding tofacitinib’s cancer risk when used for rheumatoid arthritis, ulcerative colitis, Crohn’s diseas...

Full description

Bibliographic Details
Main Authors: Cristina Bezzio, Marta Vernero, Davide Giuseppe Ribaldone, Eleonora Alimenti, Gianpiero Manes, Simone Saibeni
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Cancers
Subjects:
tofacitinib
drug safety
malignancy risk
IMIDs
biologics
therapy
Online Access:https://www.mdpi.com/2072-6694/15/8/2197

Internet

https://www.mdpi.com/2072-6694/15/8/2197

Similar Items